Text trial breast
Web1 Jul 2016 · Purpose: Risk of recurrence is the primary consideration in breast cancer adjuvant therapy recommendations. The TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive breast cancer, testing … Web7 Aug 2003 · PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer. Detailed Description: OBJECTIVES:
Text trial breast
Did you know?
WebMore recently, Sjöström and colleagues developed the Adjuvant Radiotherapy Intensification Classifier (ARTIC) transcriptomic signature from the SwBCG91-RT trial, in which patients with node-negative stage I–II breast cancer were randomly assigned after breast-conservative surgery to receive whole-breast adjuvant radiation therapy or not . WebThe findings, based on an average 12 to 13-year follow-up of patients in the trials, was presented at the 2024 San Antonio Breast Cancer Symposium. The IBCSG-led …
WebThe results were updated in 2024 after approximately 8-9 years median follow-up and are the basis for this analysis. * Details of the analyses for this web application were published in the Journal of Clinical Oncology . * This web application was made possible by grants from the Friends of Dana-Farber Cancer Institute and the Breast Cancer ... Web9 Dec 2024 · The breast cancer-free interval (BCFI) in this study did not differ significantly from the BCFI in a cohort of patients derived from the SOFT and TEXT trials (hazard ratio [HR], 0.81; 95% CI, 0.57 ...
Web1 day ago · Anthracycline plus taxane regimens are most efficacious at reducing breast cancer recurrence and death. Regimens with higher cumulative doses of anthracycline … Web11 Dec 2014 · In 2003, the International Breast Cancer Study Group (IBCSG) initiated two randomized, phase 3 trials, the Suppression of Ovarian Function Trial (SOFT) and the …
Web14 Apr 2024 · Hormone receptor (HR)-positive, HER2/neu-negative breast cancers have a sustained risk of recurrence up to 20 years from diagnosis. TEAM (Tamoxifen, Exemestane Adjuvant Multinational) is a large, multi-country, phase III trial that randomized 9776 women for the use of hormonal therapy. Of these 2754 were Dutch patients. The current study …
Web4 Apr 2016 · The TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) trials investigated adjuvant endocrine therapies for … clint hullWebKey Points. Question Do Asian patients with ERBB2-positive early or locally advanced breast cancer benefit from the addition of pertuzumab to trastuzumab and docetaxel in the neoadjuvant setting, compared with placebo, trastuzumab, and docetaxel?. Findings In this randomized clinical trial of 329 women with early or locally advanced breast cancer, total … clint hummel imdbWeb7 Mar 2024 · Joyce O’Shaughnessy, MD, leads a discussion on SABCS 2024 updates from the SOFT and TEXT trials for premenopausal women with HR-positive breast cancer. EP: … clint hummelWebHistorical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT. Regan MM, Niman SM, Fleming GF, … clint hurdle baseball cardWebBIG 2-02 / BIG 3-02. Suppression of Ovarian Function (SOFT) with either tamoxifen or exemestane compared with tamoxifen alone in treating premenopausal women with … clint hurdle biobobby\\u0027s bbq crispsWeb5 Dec 2012 · Our main analyses of breast cancer outcomes involve only the 6846 women with ER-positive disease (sensitivity analyses shown in the appendix include the other women); side-effect analyses include all 12 894 women, regardless of whether the ER status of their disease was positive, negative or unknown. Methods Study design and participants clint hurdle autographed baseball